Changing Of The Guard At US FDA Continues With Unger Retirement

 
• By Michael McCaughan

One of the US FDA’s most prominent review managers is retiring after nearly 25 years with the agency. Ellis Unger’s departure underscores a sense of transition in the leadership and mindset of the drug center.

FDA building
The next director of the FDA's Office of Cardiology, Hematology, Endocrinology and Nephrology following Ellis Unger's retirement remains unclear.

More from US FDA

More from Agency Leadership